Pioneer the next chapter of interventional vascular medicine with robotic assistance

We work closely with healthcare professionals to develop robotic solutions for treating vascular diseases such as heart attack and stroke. Our first solution, R-One™, is designed to assist with PCI, the gold standard for coronary artery diseases.

Learn more about R-One Clinical results

This robotic unit perfectly reproduces hand movements and enhance medical procedures.
Navigation is extremely precise, optimizing the placement of balloons and stents.
The guidewire locking system guarantees secure access to the lesion throughout the procedure.

Enhance
medical procedures thanks to robotic assistance

ROBOTIC PRECISION (R-GRASP®, R-LOCK®)
ENHANCED NAVIGATION (EASY-LOOP®, R-BOOST®, R-FREE®)
INTUITIVE CONTROL
OPEN ARCHITECTURE*
*compatibility with market leading devices (guidewires and stent/balloon catheters) and cath labs (imaging systems)
QUICK SET-UP (EASY-CLICK®)

The control unit allows physicians to manipulate instruments remotely. They can thus be protected from x-rays, known to cause serious diseases such as cancer².
The doctor can carry out procedures in a completely safe environment, while comfortably seated.
² Brain and neck tumors among physicians performing interventional procedures (2013)

Improve
staff comfort and safety

RADIO-STOP®: TOTAL RADIOPROTECTION
CLOSE VISUALIZATION
COMFORTABLE SITTING POSITION

Doctor J. Fajadet, co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress and Director of the EAPCI
R-One™ is a very intuitive tool. Getting started is very fast and simple. In particular, R-One™ allows instruments to be locked into place, so you never lose access to the lesion. It brings a significant revolution in our profession.

Doctor R. Sabatier, interventional cardiologist at Caen University Hospital (France)
Getting started is very easy and intuitive. The fact that the robot’s behavior is consistent and means the risk of human error can be reduced.

Professor A. Cribier, Former Chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI
R-One™ represents a major step forward in interventional cardiology. This technology really impressed me and will give strong benefits to the healthcare system.

Doctor A. Cremonesi, head of the Villa Maria hospital cardiovascular department in Bologna (Italy) and active member of EuroPCR Board
This robotic platform is very impressive. It’s the future of our profession, not only for interventional cardiology, but also for peripheral vascular and neurovascular procedures.

Learn more

Previous Next

News

18 May 2022

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

+

11 January 2022

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

+

Events

About Robocath

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotics industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions. R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs. In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (major adverse cardiovascular events). R-One received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa. Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. Based in Rouen, France, Robocath has more than 70 employees.